Enlivex Therapeutics Ltd.
ENLV · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | — | -777.00K | -25.80M | -31.06M | -34.65 |
| 2023 FY | — | -835.00K | -29.40M | -29.07M | -23.40 |
| 2024 FY | — | -545.00K | -15.54M | -15.01M | -10.95 |
| 2025 FY | — | -332.00K | -15.00M | 1.24B | 405.60 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 67.64M | 10.80M | 49.95M | 4.85M | 56.84M |
| 2023 FY | 36.83M | 6.75M | 813.00K | 1.03M | 30.08M |
| 2024 FY | 27.69M | 4.10M | 3.30M | 534.00K | 23.59M |
| 2025 FY | 2.33B | 392.05M | 2.01M | 641.00K | 1.93B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -23.95M | -8.12M | -32.08M | — | 38.72M |
| 2023 FY | -23.52M | -236.00K | -23.76M | — | -49.13M |
| 2024 FY | -13.01M | -103.00K | -13.11M | — | 2.51M |
| 2025 FY | -10.42M | -68.00K | -10.48M | — | -1.41M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 72.48M | 27.38M | — | — | — |
| 2023 FY | 50.15M | 50.37M | — | — | — |
| 2024 FY | 24.00M | 21.23M | — | — | — |
| 2025 FY | 32.14M | 30.77M | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q1 | — | -90.00K | -3.53M | -3.45M | -2.40 |
| 2025 Q2 | — | -85.00K | -3.08M | -1.87M | -1.17 |
| 2025 Q3 | — | -81.00K | -2.56M | -2.21M | -1.38 |
| 2025 Q4 | — | -76.00K | -5.86M | 1.24B | 410.25 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q1 | 24.04M | 3.41M | 2.05M | 503.00K | 20.63M |
| 2025 Q2 | 22.60M | 3.54M | 1.89M | 480.00K | 19.05M |
| 2025 Q3 | 20.94M | 3.46M | 4.20M | 701.00K | 17.48M |
| 2025 Q4 | 2.33B | 392.05M | 2.01M | 641.00K | 1.93B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q1 | -4.62M | -32.00K | -4.66M | — | -1.25M |
| 2025 Q2 | -1.20M | -7.00K | -1.21M | — | -129.00K |
| 2025 Q3 | -1.97M | -23.55K | -2.32M | — | 2.19M |
| 2025 Q4 | -2.90M | -9.38K | -2.91M | — | -2.19M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q1 | 21.24M | 19.69M | — | — | — |
| 2025 Q2 | 26.72M | 25.31M | — | — | — |
| 2025 Q3 | 25.01M | 21.51M | — | — | — |
| 2025 Q4 | 31.96M | 30.60M | — | — | — |